HyperCKemia and rhabdomyolysis in the neuroleptic malignant and serotonin syndromes: A literature review
Publication year
2020Source
Neuromuscular Disorders, 30, 12, (2020), pp. 949-958ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Neurology
Pharmacology-Toxicology
Human Genetics
Internal Medicine
Journal title
Neuromuscular Disorders
Volume
vol. 30
Issue
iss. 12
Page start
p. 949
Page end
p. 958
Subject
Radboudumc 12: Sensory disorders DCMN: Donders Center for Medical Neuroscience; Radboudumc 18: Healthcare improvement science RIHS: Radboud Institute for Health Sciences; Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience; Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences; Human Genetics - Radboud University Medical Center; Internal Medicine - Radboud University Medical Center; Neurology - Radboud University Medical Center; Pharmacology-Toxicology - Radboud University Medical CenterAbstract
Neuroleptic malignant syndrome and serotonin syndrome are two syndromes whose molecular bases remain poorly understood. The phenotypes of both syndromes overlap with other syndromes that have a clear genetic background, in particular RYR1-related malignant hyperthermia. Through a literature review, performed according to the PRISMA guidelines, we aimed to report the clinical features of both syndromes, and the results of genetic testing performed. 10 case series and 99 case reports were included, comprising 134 patients. A male predominance of 58% was found. The median age was 35 (range 4-84) years. Eight patients experienced recurrent episodes of rhabdomyolysis. Genetic analysis was performed in eleven patients (8%), revealing four RYR1 variants, three likely benign (p.Asp849Asn, p.Arg4645Gln, p.Arg4645Gln) and one variant of uncertain significance (p.Ala612Thr). This review underlines that a subset of patients with neuroleptic malignant syndrome and serotonin syndrome develop recurrent episodes of rhabdomyolysis. This recurrent pattern suggests a possible underlying (genetic) susceptibility. However, the genetic background of neuroleptic malignant syndrome and serotonin syndrome has only been investigated to a very limited degree so far. The increasing availability of next generation sequencing offers an opportunity to identify potentially associated genetic backgrounds, especially in patients with recurrent episodes or a positive family history.
This item appears in the following Collection(s)
- Academic publications [243399]
- Electronic publications [129936]
- Faculty of Medical Sciences [92493]
- Open Access publications [104460]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.